In both cases, fasting male CD-1 mice aged 5 or 6 weeks from the same vendor were used. The specification would have been saved because a decrease in lethality had no effect. Synthetic lethality is a situation in which a mutation in one of the two genes separately still supports cell viability, but the combination of the two mutations leads to cell death. If one of these genes is important for a cancer, then the discovery of the second entity capable of producing a synthetic lethal interaction should be both highly effective and highly selective in causing cancer cell death, since cells containing a normal copy of either gene should not be affected.3, 8 Real-world scenarios are more complicated than conceptualizations, and many questions about synthetic lethality have yet to be answered. At the top of this list are (1) how to find the most accessible targets for this type of attack, and (2) whether cancer cell selectivity can be achieved by inhibiting proteins that are also important for cellular homeostasis. In addition, researchers are just beginning to identify quantitative and qualitative biochemical differences between cancer cells and normal cells. In the absence of clear patterns of impairments or mutagenic changes, as seen in some familial cancers, it is still difficult today to detect overlapping but slightly different functionalities of paralogous proteins.3 Synthetic lethality refers to a situation where the loss of one of the two genes has little or no effect. But the combination of the loss of both genes is fatal [32]. In a cancer cell, a genetic change, such as a defect in a tumor suppressor gene, can make a second gene essential for cell survival. Targeting the product of this second gene could be deadly for cancer cells, but relatively non-toxic to normal cells.

For questions of the second type, cyanide tests are carried out as limit tests when slight shifts (especially upward changes) in the LD50 are of little importance. Only five animals are tested at a fixed limit dose. Depending on how often the material is screened, an occasional animal may die, as the MLD is usually in the LD01 range. Therefore, if an animal dies, the test must be repeated before continuing. If the result is the same, or if more than one animal dies during the first border trial, there is cause for concern and the material should not be released until the cause of the increased lethality is understood. It should be noted that these tests are in no way a substitute for chemical analyses. No conclusions can and should not be drawn on the quantities or concentrations of active substances in a preparation on the basis of lethality data alone. Lethality tests were first used to standardize biological and/or botanical drug preparations. This is indeed a practice that continues to this day. The FDA requires certain compounds to be released batch by batch and expects the LD50 to appear in the release documentation. Pharmaceutical companies can perform final lethality testing on fully synthetic finished formulations before they are released for clinical or wholesale trials.

Finished foods are often tested in batches before distribution. Quality control screenings are simple in that they are performed to ensure the quality of a particular batch of product prior to human exposure. They do not provide data to draw general conclusions about the safety of a well-manufactured product. Logs contain predefined expectations of what constitutes a „success“ or „failure.“ Quality assurance screens can be divided into two different categories. The first consists of those made with standardized materials of biological origin for efficiency. The second consists of these tests for gross contamination or adulteration, i.e. „a cyanide test“. Another way to look at these two different tests is that the first is a two-sided question: For example, is the test batch of a vaccine more or less effective (and in this case, the endpoint is death) than a known standard? In the second, the question is one-sided: does the material have a surprisingly high lethal power? The authors have little practical experience in using lethality data for the standardization of biological material. We therefore limit our comments on quality assurance testing issues to protocols for detecting coarse impurities or falsifications. Traditional protocols can sometimes provide unnecessarily complicated data for quality control testing.